DK2085093T3 - Præparat, der indeholder stærkt oprenset botulinumtoksin type a opnået fra infant botulisme-patogen - Google Patents

Præparat, der indeholder stærkt oprenset botulinumtoksin type a opnået fra infant botulisme-patogen Download PDF

Info

Publication number
DK2085093T3
DK2085093T3 DK07830661.0T DK07830661T DK2085093T3 DK 2085093 T3 DK2085093 T3 DK 2085093T3 DK 07830661 T DK07830661 T DK 07830661T DK 2085093 T3 DK2085093 T3 DK 2085093T3
Authority
DK
Denmark
Prior art keywords
toxin
botulinum
medicament
botulinum toxin
disease
Prior art date
Application number
DK07830661.0T
Other languages
English (en)
Inventor
Ryuji Kaji
Shunji Kosaki
Tetsuhiro Harakawa
Yasushi Torii
Yoshitaka Goto
Miho Shinmura
Sachio Okuda
Hirotoshi Nakano
Original Assignee
Chemo Sero Therapeut Res Inst
Univ Tokushima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39324650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2085093(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemo Sero Therapeut Res Inst, Univ Tokushima filed Critical Chemo Sero Therapeut Res Inst
Application granted granted Critical
Publication of DK2085093T3 publication Critical patent/DK2085093T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (7)

1. Medikament, der omfatter et blokerende middel for neuromuskulær transmission, der som aktiv bestanddel omfatter et stærkt oprenset type A-neurotoksin af en HA-negativ Clostridium botulinum type A, der er isoleret som infant botulisme-patogen og har en molekylvægt på 150 kDa, til anvendelse til behandling af en sygdom med en muskeloveraktivitet.
2. Anvendelse af et blokerende middel for neuromuskulær transmission, der som aktiv bestanddel omfatter et stærkt oprenset type A-neurotoksin af en HA-negativ Clostridium botulinum type A, der er isoleret som infant botulisme-patogen og har en molekylvægt på 150 kDa, til fremstilling af et medikament til behandling af en sygdom med en muskeloveraktivitet.
3. Medikament til anvendelse ifølge krav 1 eller anvendelse ifølge krav 2, hvor det blokerende middel for neuromuskulær transmission har en bredere sikkerhedsmargin og fremviser en hurtigere effektivitet og en mindre diffusionsegenskab end botulinumtoksin LL, L og M.
4. Medikament til anvendelse ifølge krav 1 eller 3 eller anvendelse ifølge krav 2 eller 3, hvor det stærkt oprensede neurotoksin er produceret af en hvilken som helst HA-negativ stamme af Kyoto-F, Chiba-H, Y-8036, 7I03-H, 7I05-H eller KZ1828, der stammer fra infant botulisme-patogen.
5. Medikament til anvendelse ifølge krav 1, 3 eller 4 eller anvendelse ifølge et hvilket som helst af krav 2 til 4, hvor det blokerende middel for neuromuskulær transmission yderligere omfatter et stabiliseringsmiddel for botulinumtoksin.
6. Medikament til anvendelse eller anvendelse ifølge krav 5, hvor stabiliseringsmidlet er human serumalbumin.
7. Medikament til anvendelse ifølge et hvilket som helst af kravene 1 og 3 til 6 eller anvendelse ifølge et hvilket som helst af kravene 2 til 6, hvor sygdommen med en muskeloveraktivitet er en sygdom, der induceres af lokal overaktivitet, hvilken sygdom er udvalgt blandt strabismus, blefarospasme, hemifacial spasme, spasmodisk torticollis, spasticitet efter apopleksi, cerebral parese, spasmodisk dysfoni, hovedpine, såsom migræne, kroniske smerter, såsom lumbago, stivhed i skuldrene, parese, der forekommer ved starten af Parkinsons sygdom eller multipel sklerose, myofascielt smertesyndrom, spasme af tyggemusklerne, kronisk analfissure, overaktiv blære, bruxismus, facial myokymia, tic, lokal dystoni eller rynke.
DK07830661.0T 2006-10-27 2007-10-26 Præparat, der indeholder stærkt oprenset botulinumtoksin type a opnået fra infant botulisme-patogen DK2085093T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006293173 2006-10-27
PCT/JP2007/070927 WO2008050866A1 (en) 2006-10-27 2007-10-26 Preparation containing highly purified botulinum toxin type a derived from infant botulism pathogen

Publications (1)

Publication Number Publication Date
DK2085093T3 true DK2085093T3 (da) 2015-06-01

Family

ID=39324650

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07830661.0T DK2085093T3 (da) 2006-10-27 2007-10-26 Præparat, der indeholder stærkt oprenset botulinumtoksin type a opnået fra infant botulisme-patogen

Country Status (9)

Country Link
US (1) US9278133B2 (da)
EP (1) EP2085093B1 (da)
JP (1) JP5634675B2 (da)
CA (1) CA2667536C (da)
DK (1) DK2085093T3 (da)
ES (1) ES2537579T3 (da)
PL (1) PL2085093T3 (da)
PT (1) PT2085093E (da)
WO (1) WO2008050866A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009123174A1 (ja) 2008-03-31 2011-07-28 一般財団法人化学及血清療法研究所 Ａ２型ボツリヌス神経毒素製剤
WO2010013495A1 (ja) * 2008-07-31 2010-02-04 財団法人化学及血清療法研究所 高度精製ボツリヌス毒素治療剤を有効成分として含有する薬学的組成物およびその利用
JPWO2010013494A1 (ja) * 2008-07-31 2012-01-05 一般財団法人化学及血清療法研究所 軸索輸送されないボツリヌス神経毒素製剤を含有する医薬組成物およびその利用
JP2011074025A (ja) * 2009-09-30 2011-04-14 Chemo-Sero-Therapeutic Research Inst ボツリヌス毒素の精製方法
CA2773396C (en) * 2009-10-21 2020-12-15 Revance Therapeutics, Inc. Methods and systems for purifying non-complexed botulinum neurotoxin
KR101134146B1 (ko) * 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
WO2001013357A1 (en) 1999-08-16 2001-02-22 Ekos Corporation Ultrasound assembly for use with a catheter
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
WO2003082315A1 (fr) 2002-03-29 2003-10-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Remede contre l'hypermyotonie
JP2005154407A (ja) * 2003-06-20 2005-06-16 Santen Pharmaceut Co Ltd 筋緊張亢進性疾患の治療剤
WO2004112821A1 (ja) 2003-06-20 2004-12-29 Santen Pharmaceutical Co., Ltd. 筋緊張亢進性疾患の治療剤
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
JPWO2009123174A1 (ja) * 2008-03-31 2011-07-28 一般財団法人化学及血清療法研究所 Ａ２型ボツリヌス神経毒素製剤
FR2930447B1 (fr) * 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US8440505B2 (en) * 2009-01-29 2013-05-14 International Business Machines Corporation Semiconductor chips including passivation layer trench structure

Also Published As

Publication number Publication date
EP2085093B1 (en) 2015-02-25
WO2008050866A1 (en) 2008-05-02
JP5634675B2 (ja) 2014-12-03
CA2667536C (en) 2016-05-03
PT2085093E (pt) 2015-06-26
EP2085093A1 (en) 2009-08-05
US20100173841A1 (en) 2010-07-08
US9278133B2 (en) 2016-03-08
EP2085093A4 (en) 2012-01-18
CA2667536A1 (en) 2008-05-02
PL2085093T3 (pl) 2015-10-30
JPWO2008050866A1 (ja) 2010-02-25
ES2537579T3 (es) 2015-06-09

Similar Documents

Publication Publication Date Title
Samizadeh et al. Botulinum neurotoxin formulations: overcoming the confusion
Kumar et al. The botulinum toxin as a therapeutic agent: molecular structure and mechanism of action in motor and sensory systems
EP1508336B1 (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
JP2019108381A (ja) クロストリジウム毒素医薬組成物
DK2085093T3 (da) Præparat, der indeholder stærkt oprenset botulinumtoksin type a opnået fra infant botulisme-patogen
Ferrari et al. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal
Poulain et al. Clostridial neurotoxins: from the cellular and molecular mode of
Pagan et al. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A
Thakker et al. Pharmacology and clinical applications of botulinum toxins A and B
Wortzman et al. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use
US9623075B2 (en) Type A2 botulinum toxin preparation
JP2011157331A (ja) 高用量投与が可能なボツリヌス毒素製剤
Callaway et al. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology
AU2019253771A1 (en) Clostridial toxin pharmaceutical compositions
US11957740B2 (en) Complex of botulinum neurotoxin E and its binding protein as a formulation with enhanced potency
Aoki Pharmacology, immunology, and current developments
US20210353725A1 (en) Therapeutic and Cosmetic Uses of Botulinum Neurotoxin Serotype E
Frevert et al. Conversion and Calculations between Different Commercial Toxin Products
US20200330563A1 (en) Botulinum neurotoxin a subtype 6 and pharmacological methods of use
Truong et al. Pharmacology of Botulinum Toxin Therapy
Cornelia et al. Botulinum toxins: transformation of a toxin into a treatment
Lew Botulinum toxin type B (Myobloc™, NeuroBloc™): a new choice in cervical dystonia
Eleopra et al. 6 Biology and Clinical Pharmacology of Botulinum Neurotoxin Type C and Other Non-A/Non-B Botulinum
Tintner et al. Botulinum toxin
Albanese The current status and use of botulinum toxins